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Summary Single-chain Fv (scFv) molecules exhibit highly specific tumour-targeting properties in tumour-bearing mice. However, because of
their smaller size and monovalent binding, the quantities of radiolabelled scFv retained in tumours limit their therapeutic applications.
Diabodies are dimeric antibody-based molecules composed of two non-covalently associated scFv that bind to antigen in a divalent manner.
In vitro, diabodies produced from the anti-HER2/neu (c-erbB-2) scFv C6.5 displayed approximately 40-fold greater affinity for HER2Ineu by
surface plasmon resonance biosensor measurements and significantly prolonged association with antigen on the surface of SK-OV-3 cells
(tl,2 cell surface retention of > 5 h vs 5 min) compared with C6.5 scFv. In SK-OV-3 tumour-bearing scid mice, radioiodinated C6.5 diabody
displayed a highly favourable balance of quantitative tumour retention and specificity. By as early as 4 h after i.v. administration, significantly
more diabody was retained in tumour (10 %ID g-1) than in blood (6.7 %ID ml-') or normal tissue (liver, 2.8 %ID g-'; lung, 7.1 %ID g-1; kidney,
5.2 %ID g-1). Over the next 20 h, the quantity present in blood and most tissues dropped approximately tenfold, while the tumour retained
6.5 %ID g-1 or about two-thirds of its 4-h value. In contrast, the 24-h tumour retention of radioiodinated C6.5 scFv monomer was only
1 %ID g-1. When diabody retentions were examined over the course of a 72-h study and cumulative area under the curve (AUC) values were
determined, the resulting tumor-organ AUC ratios were found to be superior to those previously reported for other monovalent or divalent
scFv molecules. In conclusion, the diabody format provides the C6.5 molecule with a distinct in vitro and in vivo targeting advantage and has
promise as a delivery vehicle for therapeutic agents.
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A major goal ofantibody-based cancer therapy has been to specifi-
cally deliver toxic payloads, such as radioisotopes, toxins or drugs,
to tumours. The range of antibody binding site-based molecules
includes IgM (1000 kDa), IgG (150 kDa), F(ab')2 (100 kDa), Fab
(50 kDa), (scFv')2 (55 kDa) and scFv (25 kDa). In immunodefi-
cient mice, larger molecules such as IgG and F(ab')2 fragments are
retained at high levels in human tumour xenografts with a low
degree ofspecificity (Milenic etal, 1991; Adams et al, 1992), while
smaller molecules such as scFv, (scFv')2 and Fab are retained in
tumour at comparatively lower levels with greatly improved speci-
ficity (Beaumier et al, 1985; Colcher et al, 1990; Milenic et al,
1991; Adams et al, 1993). The most prominent determinant of the
above targeting properties is the size of the antibody-based mole-
cule relative to the renal threshold for first-pass clearance. Another
important feature ofantibody-based molecules is valence, as signif-
icantly greater tumour retention has been associated with multiva-
lent binding to target antigen (Milenic et al, 1991; Adams et al,
1993, 1996; Wolfet al, 1993). Recently, attention has focused upon
the generation of divalent scFv-based molecules with molecular
weights in the range of the renal threshold for first-pass clearance.
These include 50-kDa diabodies (Holliger, 1993), 55-kDa (scFv')2
(Adams et al, 1993), 60 to 65-kDa amphipathic helix-based scFv
dimers (Pack et al, 1992, 1993) and 80-kDa (scFv-CH3)2 LD mini-
bodies and Flex minibodies (Hu Shi-zhen et al, 1996). While each
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ofthese proteins is capable ofbinding two antigen molecules, they
differ in the orientation, flexibility and span oftheirbinding sites.
In this report, we examine the potential ofdiabody molecules to
function as vehicles for the specific, quantitative delivery of
radioisotopes to tumours. Diabodies are scFv dimers in which each
chain consists of a variable heavy (VH) domain connected to a
variable light (VL) domain using a peptide linker that is too short
to permit pairing between domains on the same chain (Holliger et
al, 1993). Consequently, pairing occurs between complementary
domains of two different chains, creating a stable non-covalently
bound dimer with two binding sites (Figure 1) (Perisic etal, 1994).
We have used the human anti HER2/neu (c-erbB-2) scFv C6.5
(Schier et al, 1995) to construct a C6.5 diabody. While HER2/neu
expression on normal human tissues is limited, it is overexpressed
in a number of cancers, including breast and ovarian carcinoma
(King et al, 1985; Kraus et al, 1987; van de Vijver et al, 1987;
Berchuck et al, 1990), gastric tumours and colon adenocarcinomas
(Yokota et al, 1988). Its relevance as a target for antibody-based
therapy is further underscored by the correlation of HER2/neu
overexpression with a poor prognosis in several malignancies
(Slamon et al, 1987; Allred et al, 1992). Here, we present the C6.5
diabody's in vitro binding characteristics and in vivo distribution
in tumour-bearing scid mice.
METHOD
C6.5 scFv and diabody production
The C6.5 scFv in pUC119mycHis was expressed from E. coli
TG1 and purified by immobilized metal chelate chromatography
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Figure 1 The structures of an IgG molecule (-150 kDa), an Fv fragment (-22 kDa), a recombinant scFv (-25 kDa) molecule, a dimeric (scFv')2 molecule
(-55 kDa) and a diabody molecule (-50 kDa) are presented. While they are identical, the two diabody components are illustrated with different shading to clarify
the structure
(IMAC) followed by fast protein liquid chromatography (FPLC)
size-exclusion chromatography using a Superdex 75 column as
previously described (Schier et al, 1995). To create the C6.5
diabody, the C6.5 VH andV. genes werejoined together by poly-
merase chain reaction (PCR) splicing by overlap extension using
an oligonucleotide that encoded a five amino acid linker (G4S)
between the C-terminus of the VH and the N-terminus of the VA
gene. First, the C6.5 VH and V. genes were amplified using PCR
from C6.5 scFv DNA using the primers LMB3 and DIAFOR (5'-
CCA CCT GAG GAG ACG GTG ACC-3') (Marks etal, 1991) for
the VH gene and LMB2 and DIABACK (5'-GGT CAC CGT CTC
CTC AGG TGG AGG CGG TTC ACA GTC TGT GTT GAC
GCA GCC G-3') (Marks et al, 1991) for theV. gene. The VH and
V. genes were gel purified and 200 ng ofeach combined in a 50-,ul
reaction with 5 U of Vent DNA polymerase (New England
Biolabs). The reaction mixture was cycled seven times tojoin the
fragments (94°C for 1 min, 50°C for 1 min, 72°C for 1.5 min) after
which 20pM ofthe primers LMB2 and LMB3 were added, and the
reaction cycled 25 times to amplify the products. The resulting
diabody gene product was digested with NcoI and NotI, gel puri-
fied and ligated into NcoIINotI-digested pUC 1l9mycHis (Schier
et al, 1995). The ligation mixture was used to transform E. coli
TG1, and clones containing the correct insert identified by PCR
screening and DNA sequencing. Native diabody was expressed
(Breitling, 1991) and purified from the bacterial periplasm using
IMAC (Hochuli et al, 1988) followed by FPLC size-exclusion
chromatography using a Superdex 75 column.
Measurement of C6.5 scFv and diabody affinity for
c-erbB-2
The affinities of C6.5 scFv and C6.5 diabody for the HER2/neu
ECD were determined using surface plasmon resonance in a
BlAcore (Pharmacia, Sweden) generally as previously described
(Schier et al, 1995, 1996). In a BlAcore flow cell, approximately
1400 RU (for the scFv) or 600 RU (for the diabody) ofHER2/neu
ECD (90 kDa; McCartney, 1994) were coupled to a CM5 sensor
chip (J0nsson et al, 1991). Association rates were measured under
continuous flow of 5 pl min-1 using concentrations ranging from
5.0 x 10-8 to 8.0 x 10-7 M. k1on was determined from a plot of [In
(dR/dt)]/t vs concentration (Karlson et al, 1991). Dissociation rates
were measured using aconstant flow of25 pl min-' and an scFv or
diabody concentration of 1.0 x 10- M. Density ofHER2/neu ECD
on the sensorchip surface was calculated to be 4.2 x 103 molecules
pm 2, assuming 600 RU = 0.007 pmol HER2/neu mm-2
Cell-surface retention assay
In order to assess the impact of the divalent nature of the C6.5
diabody on its association with cell-bound HER2/neu, an in vitro
cell-surface retention assay was performed. For this assay, the
C6.5 scFv and diabody were biotinylated using an ImmunoPure
NHS-LC-Biotinylation kit (no. 21430, Pierce, Rockford, IL,
USA). Twelve micrograms of biotinylated C6.5 scFv or diabody
were incubated with 1.2 x 107 HER2/neu-overexpressing SK-OV-
3 (HBT 77; American Type Culture Collection, Rockville, MD,
USA) cells (Weiner et al, 1993) in a total volume of 0.5 ml of
FACS buffer (0.154 M sodium chloride, 10 mm sodium phosphate,
1% bovine serum albumin, 0.1% sodium azide, pH 7.2) for 30 min
at room temperature. The cells were centrifuged at 500g for 5 min
at 4°C, washed with 10 ml ofice-cold FACS buffer two times and
then resuspended gently in 12 ml ofFACS buffer at 37°C. The cell
suspensions were then incubated at 37°C with gentle shaking in a
water bath. To decrease the rebinding of dissociated biotinylated
diabody or scFv to the cells, at 15, 30, 45, 60, 90 and 120 min after
commencing the incubation the suspensions were pelleted at
500 g, the supematants were aspirated and the cells were gently
resuspended in fresh FACS buffer (37°C). Immediately after each
round of pelleting and resuspension, 0.5-ml aliquots containing
5 x 105 cells were removed in triplicate (i.e. at 0, 15, 30, 45, 60, 90
and 120 min), placed on ice for 5 min and centrifuged at 500g for
5 min at 4°C. After removing the supernatants from the aliquots,
the cells were gently resuspended in 50p1 ofice-cold FACS buffer
containing 50pl of a 1:800 dilution of streptavidin-PE, incubated
on ice for 30 min and washed twice with FACS buffer at 4°C. The
cells were fixed with 1% paraformaldehyde and the degree of
fluorescence was determined by analysis on a FACscan flow
cytometer (Becton Dickinson, San Jose, CA, USA) as described
(Weiner et al, 1993). koff was calculated assuming first-order
kinetic using the formula F, = (F) x (e-kt), where F, = fluorescence
at time t, F = fluorescence at time 0 and k = k,ff. t112 was calculated
from koff using F/F, = 0.5. Density ofHER2/neu on the surface of
SK-OV-3 cells was calculated to be 3.2-4.8 x 103 moleculesjim-2,
assuming a cell diameter of 10 ,um and 1.0 x 106 HER2/neu ECD
per cell (observations ranged from 1.0 x 106 to 1.5 x 106 in
Scatchard assays; unpublished data).
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immunoreactivity of the radiopharmaceuticals was evaluated by
SDS-PAGE, high-performance liquid chromatography (HPLC) on
nt e i )a Superdex 75 column (Pharmacia) and in a live-cell binding assay
as described (Adams et al, 1993). The immunoreactivities of the
radiolabelled diabody and scFv monomer were found to be 87.6%
scFv and 65.3% respectively. The differences in immunoreactivity most
likely reflect the prolonged association of the diabody with its
antigen on the cell surface. Six- to eight-week-old CB.17 Icr scid
mice were obtained from the Fox Chase Cancer Center Laboratory
Animal Facility. Then, 2.5 x 10'1 human ovarian carcinoma SK-OV-
3 cells were implanted s.c. on the abdomen of each mouse. When
the tumours had achieved a size of 50-200 mg (approximately 8
weeks), Lugol's solution was placed in theirdrinking watertoblock
thyroid accumulation of radioiodine, and biodistribution studies
were initiated. Twenty micrograns (100,ul) of radioiodinated
(.4~j~J~j3J diabody or scFv were administered by i.v. tail vein injection to each
Diabody mouse. Cohorts offive mice thathadreceived the'251-C6.5 diabody
were sacrificed at 1, 4, 24, 48 and 72 h after injection and a single
cohort of five mice that had received the '25I-C6.5 scFv monomer
was sacrificed at 24 h afterinjection. The mean and s.e.m. ofreten-
tion of each radiopharmaceutical in tissue (%ID g-') and blood
(%ID ml-') was determined as described (Adams et al, 1993).
Calculations of the estimated cumulative localization (AUC) of
10 15 20 25 30 35 40 diabody in tissues and blood were determined using the NCOMP
program (Laub, 1996). t,,2a and t,,2IB were calculated using the
lime (min) Rstrip program (Micromath, Salt Lake City, UT, USA).
.C profiles of the C6.5 diabody and C6.5 scFv. After IMAC Significance levels were determined using a Student's t-test on the
a Ni++ agarose column, the C6.5 diabody and scFv were Statworks program (Cricket Software, Philadelphia, PA, USA).
RESULTS
Diabody expression and characterization
The C6.5 diabody and scFv were secreted from E. coli grown in
shake flasks with typical yields of native protein after IMAC and
HPLC purification ofapproximately 1.0 mg 1- for the diabody and
5 mg 1-1 for the scFv. The C6.5 scFv eluted from a Superdex 200
column as a single peak of approximately 25 kDa, with minimal
analysed on a Superdex 200 column (Pharmacia). The C6.5 scFv eluted from
the Superdex 200 column as a single peak of approximately 25 kDa with
minimal evidence of aggregation, while the diabody eluted as a single peak of
approximately 50 kDa with no evidence of unassociated monomer
Biodistribution studies
C6.5 diabody and scFv were radiolabelled with iodine-125 using
the chloramine T (CT) method (I251IscFv = 1:6; CT/scFv = 1:10) as
previously described (Adams et al, 1992, 1993). The quality and
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Figure 3 In vitro characterization of the C6.5 diabody. C6.5 diabody and monomeric scFv were evaluated by surface plasmon resonance (BlAcore) as
described in Methods. The association and dissociation kinetics are displayed for the diabody (0) and scFv monomer (0) forms of C6.5 (A). In vitro cell-surface
retention profiles of biotinylated forms of the C6.5 diabody (0) and C6.5 monomer (0) were determined using SK-OV-3 cells, as described in the text, and the
results are displayed; s.e.m.s are less than 2% of the value presented (B)
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Figure 4 The in vivo tumour targeting of radioiodinated C6.5 diabody was
determined in a biodistribution study performed in SK-OV-3 tumour-bearing
scidmice. The plotted values represent the mean tumour (0) and blood (0)
retentions obtained from six mice per data point. The standard errors are
indicated
evidence of dimerization or aggregation (Figure 2A). The C6.5
diabody eluted from a Superdex 200 column as a single peak of
approximately 50 kDa, with no evidence of unassociated
monomer (Figure 2B). Both migrated under reducing conditions
on 12% SDS-PAGE gels as single bands ofapproximately 27 kDa
(data not shown).
The Kd of the C6.5 diabody for HER2/neu ECD was determined
by surface plasmon resonance in a BlAcore instrument to be 4.0 x
1l0 M(kon = 6.7 x 105M-l s-i;koff= 2.7 x 104 s-i) 40-fold lowerthan
the Kd of the C6.5 scFv (1.6x 10-8 M; kon = 4.0 x 105M-l s-i; koff =
6.3 x 10-3 s-i) (Figure 3A). The decrease in Kd was largely due to
reduction in koff, which correlated with a retention t12 of 43 min,
compared with 1.8 min for the scFv. In the BlAcore, the HER2/neu
ECD is chemically coupled to a three dimensional matrix of
carboxymethyl dextran, which bears little resemblance to the organi-
zation of HER2/neu on the cell surface. Therefore, the biological
relevance ofthe increased affinity ofthe diabody was determined in
an in vitro cell surface retention assay using biotinylated C6.5
diabody or scFv and human SK-OV-3 ovarian carcinoma cells over-
expressing HER2/neu. In this assay, the quantity of biotinylated
diabody or scFv retained on the surface of the SK-OV-3 cells over
time was determined by flow cytometry. Significantly longer reten-
tion ofthe C6.5 diabody was observed compared with the C6.5 scFv
(t12 scFv = 2.5 min vst12 diabody = 5 h; P < 0.001) (Figure 2B). The
results compare favourably to t12 values calculated from the koff
measured in the BlAcore of 1.8 min for the scFv and 43 min for the
diabody. Thus the increase in apparent affinity was much greater on
the cell surface than on the carboxymethyldextran surface of the
BlAcore, despite the similarities in calculated density of HER2/neu
sites (3.2-4.8 x 103 sites jtm-2 on the cell surface vs 4.2 x 103 sites
gm-2 on the sensor chip surface).
Biodistribution assays
The in vivo targeting potential ofthe C6.5 diabody was assessed in
scid mice bearing s.c. SK-OV-3 tumours overexpressing the
HER2/neu antigen. The tumour, blood and organ retention of
radioiodinated C6.5 diabody was determined at 1, 4, 24, 48 and
72 h after its i.v. administration. After the injections, the diabody
displayed a rapid equilibration phase (t,,2a = 0.67 h) and subse-
quent slower elimination phase(tl,2 , = 6.42 h) from circulation, in
a pattern characteristic of small scFv-based molecules (Figure 4).
In contrast to the blood retention properties of the diabody, the
quantity retained in tumour rose from 6.9% ID g-' at 1 hour post
Table 1 Evaluation of [1251]C6.5 diabody in tumour-bearing scidmice
C6.5 diabody C6.5 scFv
Cumulative Tumour-organ
1 h 4 h 24 h 48 h 72 h AUC AUC ratio 24 h
Tumoura 6.9 10.1 6.5 2.4 1.4 405 - 1.0
Bloodb 21.5 (0.3) 6.7 (1.5) 0.7 (9.5) 0.1 (22.5) < 0.1 (24.0) 133 3.0 0.1 (19.1)
Liver 5.7 (1.2) 2.8 (3.6) 0.3 (21.0) 0.1 (22.5) 0.1 (15.0) 137 3.0 < 0.1 (25.4)
Kidneys 16.9 (0.4) 5.2 (1.9) 1.1 (6.0) 0.4 (6.7) 0.3 (4.5) 153 2.6 0.2 (6.3)
Lung 17.0 (0.4) 7.1 (1.4) 0.7 (8.8) 0.1 (19.7) 0.1 (18.2) 57 7.1 0.1 (17.0)
Spleen 4.3 (1.6) 3.5 (3.2) 0.4 (16.1) 0.1 (20.6) 0.1 (17.0) 61 6.6 <0.1 (24.5)
Heart 13.1 (0.5) 4.7 (2.2) 0.4 (17.5) 0.1 (31.0) <0.1 (31.7) 93 4.4 <0.1 (37.2)
Stomach 4.5 (1.6) 7.9 (1.4) 1.4 (5.7) 0.3 (11.6) 0.3 (6.6) 129 3.1 0.2c (6.2)
Intestine 1.6 (4.5) 2.5 (4.6) 0.3 (22.3) 0.1 (33.4) 0.1 (24.7) 37 10.9 < 0.1 (25.8)
Bone 2.3 (3.3) 1.9 (6.0) 0.1 (40.6) < 0.1 (84.3) < 0.1 (65.0) 31 13.1 < 0.1c (34.2)
Muscle 1.2 (5.8) 1.5 (7.1) 0.2 (34.3) <0.1 (44.6) <0.1 (53.4) 37 10.9 < 0.1 (49.8)
aExpressed as %ID g-1 tissue. bExpressed as %IDml-1 blood. cs.e.m. <45%. C.B 17/ICR-scid mice bearing 50- to 200-mg s.c. SK-OV-3 tumours were used in
these studies. Cohorts of five mice per time point were given 20 9g of [1251]C6.5 diabody by i.v. injection. The mice were sacrificed at the indicated times and the
tumour, blood and normal tissue retention was determined and expressed as a percentage of the injected dose localized per g of tissue (%ID g-1) or per ml of
blood (%ID ml-') as described in Methods. Tumour-organ ratios are presented in parentheses. For each value presented, the s.e.m. was less than 30%, unless
otherwise indicated. The cumulative diabody retention (AUC) in each tissue was determined as described and is expressed in arbitrary units to facilitate the
determination of the tumour to organ AUC ratios.
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injection to a peak of 10.1 %ID g-' at 4 h post injection and slowly
decreased to 6.5% ID g-' and 1.4% ID g-' at 24 and 72 h respec-
tively (Table 1 and Figure 4). The retention of the diabody in
normal organs reflected the concentration present in blood over the
course of the study with the notable exception of the kidneys,
which function as the major elimination route for scFv-based
reagents (Table 1). The cumulative residence of the radioiodinated
diabody in tumour and normal organs, expressed as AUCs, was
determined to predict the therapeutic potential for this molecule.
Over the course of the study, favourable tumour to organ AUC
ratios were observed for a number of organs, including liver (3.0),
spleen (6.6), bone (13.1), kidneys (2.6) and blood (3:1) (Table 1).
While the activity in the bone marrow compartment is difficult to
measure directly, it is routinely estimated based upon the observa-
tion that one-fourth ofthe bone marrow compartment is composed
of blood (Siegel et al, 1990). As HER2/neu is not expressed on
cells in the marrow, the diabody will not specifically bind to
marrow, just as it does not bind to other tissues lacking HER2/neu
(e.g. liver, spleen and muscle). Therefore, the radioiodinated
diabody present in the bone marrow compartment can be solely
attributed to that present in the blood portion of the bone marrow.
Accordingly, the tumour to bone marrow ratio was estimated as
12:1 (25% of the tumour-blood ratio).
The biodistribution of the [1251]C6.5 scFv monomer was
performed at 24 h after administration for comparative purposes
and was found to be virtually identical to that previously reported
for this and other scFv monomers of similar affinity, with 1.0 % ID
g-' retained in tumour, 0.04 % ID g-I in liver and 0.05 % ID ml-' in
blood (Table 1) (Colcher et al, 1990; Milenic et al, 1991; Adams et
al, 1993; Schier et al, 1995). This clearly demonstrated the signifi-
cantly increased tumour retention (P = 0.00043) conferred by the
diabody format. The prolonged blood retention of the larger
diabody molecule may also account for some of the increased
tumour retention. This is evidenced by the 24-h tumour-blood
ratios of about 9:1 for the diabody and 20:1 for the monomer.
DISCUSSION
Here we describe the production and in vitro and in vivo properties
of the C6.5 diabody molecule specific for HER2/neu. The C6.5
diabody was expressed and purified in high yield from E. coli as
native protein without refolding. Compared with the scFv from
which it was derived, the diabody exhibited a significantly lower Kd
and slower kff from HER2/neu that was either immobilized on a
BlAcore sensorchip or as expressed on the surface oftumour cells.
In vivo, radioiodinated C6.5 diabody displayed an excellentbalance
of quantitative tumour deposition and specificity. Peak tumour
values of 10 %ID g' were observed at 4h after intravenous
administration and persisted through 24 h (6.5 %ID g-') and 72 h
(1.2 %ID g-') post injection. In contrast, the diabody was rapidly
cleared from the circulation and antigen-negative organs, as its
molecular weight (50 kDa) is less than the renal threshold. As a
result, significantly more diabody was retained in tumour than in
any other organ at all but the earliest time points studied. This
yielded tumour-normal organ AUCs of3:0 (tumor-blood) to 13.1:1
(tumour-bone). Furthermore, as we and others have previously
demonstrated, antibody-based molecules with sizes beneath the
renal threshold for first-pass clearance are typically eliminated in a
biphasic manner, with a rapid initial equilibration phase and a
slower elimination phase (reviewed in Huston et al, 1996). This
suggests that the sampling times used in this study may have
exaggerated the blood AUC value for the interval between 4 and
24 h. Thus, it is likely that the inclusion of additional sampling
times (i.e. 6, 12 and 16 h post injection) would reveal lower blood
retentions and hence, more specific tumour localization. As the
C6.5 diabody was developed from a phage display-derived scFv, a
C6.5 IgG molecule was not available for a direct comparison
between these two divalent structures. However, a reasonable
comparison can be made using an IgG molecule specific for a
different epitope on the HER2/neu antigen. We have previously
reported on the distribution of 741F8 IgG, which, like many other
monoclonal antibodies targeting cell-surface tumour-associated
antigens, exhibits a high degree of tumour uptake (e.g. 20 %ID g-')
with very poor targeting specificity (tumour-blood ratios < 1:1)
(Weiner et al, 1995). Therefore, even though the degree of tumour
retention observed with the C6.5 diabody was less than that
observed with anti-HER2/neu IgG, the increased targeting speci-
ficity associated with the diabody format results in an advantage.
Compared with the scFv, the increased tumour deposition of the
diabody could result from its increased size or increase in apparent
affinity (avidity). The increased size of the C6.5 diabody led to a
slower redistribution and elimination t12 than was observed for the
C6.5 scFv. This leads to higher blood levels and prolongation of
the concentration gradient for diffusion from blood into tumour.
However, Fab are of similar size and have similar pharmaco-
kinetics, but do not provide as great an increment in quantitative
tumour retention compared with scFv (Milenic et al, 1991; Adams
et al, 1993). Thus, size alone is unlikely to account for the
increased tumour deposition and retention of the diabody, which
instead must be at least partly due to an increase in apparent
affinity resulting from avidity. A priori, it was unclear to what
extent an increase in apparent affinity would occur with the
divalent diabody molecule. The Fab arms of the IgG molecule are
extremely flexible, because of the hinge (Ferencik, 1993). In
contrast, the two binding heads of the diabody are oriented 1800
apart in a rigid configuration (Perisic et al, 1994). Thus, the extent
to which the diabody could engage two antigens simultaneously,
particularly on the cell surface, was unclear. As determined using
surface plasmon resonance in a BlAcore, the apparent affinity of
the diabody is 40-fold higher than the scFv, largely because of a
40-fold reduction in koff. The dissociation ofdiabody from the cell
surface was sevenfold slower than observed on the BlAcore, with
a koff approximately 280-fold slower than the scFv. As the calcu-
lated antigen density on the BIAcore sensor chip surface and the
cell surface are approximately the same, these differences may
result from the greater mobility of HER2/neu ECD in the cell
membrane, leading to bivalent binding without steric strain.
Monoclonal antibody (MAb)-based radioimmunotherapy (RAIT)
has shown notable promise in the treatment of haematological
malignancies (Kaminski et al, 1993; Press et al, 1993), but progress
in the therapy of solid tumours has been hindered by a number of
factors dictated by tumour physiology (Jain, 1990). First, the disor-
dered vasculature of solid tumours leads to a heterogeneous intratu-
moral distribution of MAb. Second, the paucity of draining
lymphatics in tumours results in elevated hydrostatic pressure,
limiting the diffusion of large molecules such as IgG to 100 ,um in
1 h, 1 mm in about 2 days and 1 cm in about 7-8 months. To obtain
sufficient tumourlocalization forradiolabelled MAbtoprovide ther-
apeutic effects, the MAb must remain in circulation long enough to
diffuse from blood into tumour. At the same time, the radiolabelled
MAb must be eliminated from circulation rapidly enough to
diminish normal organ retention andpreventunacceptable toxicities.
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To achieve successful RAIT, a proper balance must be established
between these competing requirements. We hypothesized that an
appropriate balance could be accomplished by using small, high-
affinity, multivalent, antibody-based molecules. Decreasing the
size of the molecule increases both its diffusion rate into tumour
(Jain, 1990) and its rate of elimination from circulation, thus
enhancing both the degree oftumourpenetration and the specificity
of tumour retention. While the optimal size for an antibody-based
construct has yet to be identified, we believe it will fall below the
renal threshold for first-pass clearance (about 65 kDa). When
administered by acontinuous i.v. infusion, such molecules could be
maintained at steady-state levels in circulation, and controlled
gradients from blood into tumour could be established. This would
facilitate deep penetration into tumour and highly specific tumour
retention when the molecules are rapidly eliminated from circula-
tion upon the termination of the infusion. A variety of molecular
structures that span a wide range of sizes are available. These
include 80-kDa (scFv-CH3)2 minibodies (Hu Shizhen et al, 1996),
50-kDa diabodies (Holliger et al, 1993), 27-kDa scFv (Bird et al,
1988; Huston et al, 1988) and individual 12- to 13-kDa VH or VL
chains (Ward et al, 1989). While the smallest molecules will be
capable of the greatest diffusion into solid tumours, their adminis-
tration will require careful management to maintain the blood
concentrations required to permit diffusion through tumour.
Increasing the functional affinity may help 'trap' the scFv that
diffuses into tumour, localizing it long enough to facilitate thera-
peutic applications. This can be accomplished by manipulating the
intrinsic affinity properties (Schier et al, 1996) or through the
creation of multivalent binding proteins. While Weinstein has
hypothesized that the diffusion ofhigh-affinity MAb into tumouris
hindered by binding to antigen-bearing cells close to blood vessels
(Fujimori et al, 1989; Juweid et al, 1992), this may be overcome by
enhancing the diffusion gradient from blood into tumour through
the administration of large doses. Finally, the potential of engi-
neered antibody-based proteins to target tumours in humans in a
highly specific manner was recently demonstrated using radio-
immunoimaging performed by Begent et al (1996). Given that
successful tumour localization in the above study was achieved
with a small, monovalant scFv, it is our belief that the larger,
divalant diabody molecule used here will also exhibit impressive
tumour targeting in patients.
Of the divalent scFv-based molecules produced to date, before
this study, reports of in vivo assays only exist for the (scFv')2 and
theminibody. Previously, we have shown that the tumourretention
of a 20-jig dose ofthe anti-HER2/neu 741F8 (scFv')2 in scidmice
bearing relevant tumours is twice that seen with 741F8 scFv
monomer (Adams et al, 1993). While the specificity of tumour
retention at 24 h post injection was very high, as evidenced by
tumour-blood and tumour-muscle ratios of 10:1 and 75:1, respec-
tively, the quantity of (scFv')2 retained in tumour (1.6 %ID g-1)
was insufficient to mediate therapeutic effects or predict for
therapeutic dosimetry in tumours. Hu Shi-Zhen et al (1996) have
recently reported excellent selective tumour retention after the
administration of small quantities (0.1-0.2 ,ug per mouse, or
0.005-0.01 ,ug/g-' body weight) of anti-CEA (scFv-CH3)2 mini-
bodies to tumour-bearing athymic mice, with average 24-h reten-
tions of 29 %ID g-' and 8 %ID g-' in tumour with flex and LD
minibodies respectively. While the mass of the C6.5 diabody
(50 kDa) lies just below the renal threshold for first-pass clear-
ance, the two minibody species have molecularweights ofapprox-
imately 80 kDa and are above the threshold. This is evidenced by
the faster clearance ofthe diabody from circulation (0.7 %ID ml
vs 2.1 %ID ml,-1 respectively, for the diabody and minibodies at
24 h post injection), which probably leads to a lower cumulative
blood, and hence marrow, exposure for the diabody. However, the
greater peak tumour retention of the minibody leads to similar
tumour-blood AUCs forboth molecules. Clearly, the parallel eval-
uation ofidentical doses ofa series ofreagents (i.e. scFv, (scFv')2,
diabody and minibody) with identical specificity is desirable to
definitively address the role ofsize on the in vivo tumour-targeting
properties ofthese recombinant antibody-based molecules.
The cumulative retention (AUC) ofC6.5 diabody in tumour and
normal tissues was calculated to predict the therapeutic potential
of diabodies as vehicles for RAIT. RAIT efficacy is dependent
upon the delivery of lethal doses of radiation to tumour without
exceeding the doses tolerated by the bone marrow (200-300 cGy)
and organs involved in the catabolism ofthe radiopharmaceutical,
such as thekidneys (1500 cGy) andthe liver(4000 cGy) (Bentel et
al, 1989). In this study with the C6.5 diabody, we calculated
tumour to organ ratios ranging from 3:1 to 13:1. The tumour-bone
marrow estimate of 12:1 and tumour-kidney value of2.6:1 would
permit the delivery of approximately 4000 cGy to tumour at a
marrow dose of 250 cGy. This represents a significant improve-
ment over results in preclinical models observed with other anti-
body-based molecules, including scFv (Adams et al, unpublished
results), (scFv')2 (Weiner et al, 1995), Fab (Yorke et al, 1991),
F(ab')2 (Stein et al, 1991, 1994) and IgG (Stein et al, 1991;
Molthoff et al, 1991, 1992). While the predicted tumour-blood
AUCs for Flex minibodies are similar to those reported here for
the C6.5 diabody, the smaller diabody structure may confer an
advantage when penetration oflarge solid tumours is required.
As the divalent binding ofa diabody molecule to antigen on the
surface of a tumour cell molecule is dependent upon both the
density of the antigen and its orientation, it is likely that such
binding would only occur when the antigen density is high. While
the C6.5 diabody remains bound to the tumour cells in vitro
(Figure 3B) and is retained in tumour in vivo (Figure 4) signifi-
cantly longer than is its monomeric scFv form, it is likely that
diabody bound to normal tissue expressing low concentrations of
HER2/neu would bind in a monovalent manner and exhibit the
rapid dissociation kinetics characteristic of the C6.5 scFv. To
confirm this hypothesis, the in vitro and in vivo binding profiles of
C6.5 diabody and C6.5 scFv require evaluation in tumour cell
lines and tumours with a wide range ofHER2/neu expression.
Ifthe prolonged retention ofthe C6.5 diabody on the surface of
cells and in tumours overexpressing HER2/neu is mediated by
divalent binding, it may exert a direct biological impact on these
cells. Homodimerization of HER2/neu or heterodimerization of
HER2Ineu with c-erbB-3 or c-erbB-4 has recently been found to
berequired forsignal transduction afterthebinding ofheregulin to
c-erbB-3 or c-erbB-4 (Earp et al, 1995; Wallasch et al, 1995). The
possibility that divalent binding of two HER2/neu molecules by
C6.5 diabody facilitates the homodimerization of HER2/neu with
subsequent signal transduction is intriguing. Alternatively, it is
possible that cytostatic effects could be triggered by the immobi-
lization of HER2/neu on the cell surface to prevent the homo-
dimerization of the molecule's transmembrane region. Either of
these mechanisms may be responsible for reports of synergistic
effects between some anti-HER2/neu monoclonal antibodies and
chemotherapeutic agents, such as taxol orcisplatin (Hancock et al,
1991). Accordingly, the potential ofthe C6.5 diabody to dimerize
HER2/neu, trigger signal transduction and inhibit tumour cell
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growth in the presence of chemotherapeutic agents has been
studied. However, when the C6.5 diabody has been assayed for
growth inhibition potential by in vitro MTT [3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide] incorporation assays,
concentrations of up to 10 ig ml for 7 days do not significantly
inhibit the growth ofSK-OV-3 cells overexpressing the HER2/neu
antigen (unpublished results). Accordingly, it is probable that the
C6.5 diabody by itselfis not capable ofexerting cytostatic effects.
Continued improvements in antibody engineering have led to
increasingly sophisticated structures that address impediments to
successful tumourtargeting. The C6.5 diabody may be an effective
targeting vehicle for RAIT. In addition, this molecule may provide
a useful platform for the creation of affinity mutants with slower
koffrates or for the creation offusion proteins containing other anti-
bodies, cytokines, chemotactic factors or toxins.
ACKNOWLEDGEMENTS
This study was supported by National Cancer Institute (NCI) grant
CA 65559, Department of Defense (DOD) grant DAMD17-94-J-
4433, NCI grant CA06927, an appropriation from the
Commonwealth of Pennsylvania, the Bernard A and Rebecca S
Bernard Foundation, the Frank Strick Foundation and the
CaPCURE Foundation. The authors would like to thank Heidi
Simmons, Eva Horak, Anne Amoroso and James Babb of the Fox
Chase Cancer Center and Cindy Wong, Michael Yim, Donnie Tran
and Grete Hemmingder of the University of California, San
Francisco, for their expert technical assistance.
REFERENCES
Adams GP, DeNardo SJ, Amin A, Kroger LA, DeNardo GL, Hellstrom I and
Hellstrom KE (1992) Comparison ofthe pharmacokinetics in mice and the
biological activity of murine L6 and human-mouse chimeric Ch-L6 antibody.
Antibody Immunoconj Radiopharmaceut 5: 81-95
Adams GP, McCartney JE, Tai M-S, Oppermann H, Huston JS, Stafford WF,
Bookman MA, Fand I, Houston LL and Weiner LM (1993) Highly specific in
vivo tumour targeting by monovalent and divalent forms of741F8 anti-c-erbB-
2 single-chain Fv. CancerRes 53: 4026-4034
Adams GP, McCartney JE, WolfEJ, Tai M-S, Schier R, Stafford WF, Marks JD,
Bookman MA, Huston JS and Weiner LM (1996). Influence of avidity on the
tumor retention of monospecific and bispecific anti-c-erbB-2 single-chain Fv
dimers. Proc Am Assoc CancerRes 37: 472
Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osbome
CK, Tormey DC and McGuire WL (1992) Overexpression of HER-2/neu and
its relationship with other prognostic factors change during the progression of
in situ to invasive breast cancer. Hum Pathol 23: 974-979
Beaumier PL, Krohn KA, Carrasquillo JA, Eary J, Hellstrom I, Hellstrom KE, Nelp
WB and Larson SM (1985) Melanoma localization in nude mice with
monoclonal Fab against p97. JNucl Med 26: 1172-1179
Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone
LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJ and Robson L
(1996) Clinical evidence ofefficient tumor targeting based upon single-chain
Fv antibody selected from a combinatorial library. Nature Med 2: 979-984
Bentel GC, Nelson CE and Noell KT (1989) Treatment Planning and Dose
Calculation in Radiation Oncology. Pergamon Press: New York
Berchuck A, Kamel A, Whitaker R, Kems B, Olt G, Kinney R, Soper JT, Dodge R,
Clarke-Pearson DL and Marks P (1990) Overexpression ofHER2/neu is
associated with poor survival in advanced epithelial ovarian cancer. Cancer Res
50: 4087-4091
Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T,
Pope SH, Riordan GS and Whitlow M (1988) Single-chain antigen-binding
proteins. Science 242: 423-426
Breitling SD, Seehaus T, Klewinghaus I and Little M (1991) A surface expression
vector for antibody screening. Gene 104: 147-153
Colcher DR, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW,
Pantoliano MW, Milenic DE and Schlom J (1990) In viva tumor targeting of a
recombinant single-chain antigen-binding protein. JNatl Cancer Inst 82:
1191-1197
Earp HS, Dawson TL, Li X and Yu H (1995) Heterodimerization and functional
interaction between EGF receptor family members: a new signaling paradigm
with implications for breast cancer research. Breast Cancer Res Treat 35:
115-132
Ferencik M (1993) The Immunoglobulins. In Handbook (fImmunology, pp. 69-109.
Chapman & Hall: London
Fujimori K, Covell DG, Fletcher JE and Weinstein JN (1989) Modeling analysis of
the global and microscopic distribution ofimmunoglobulin G, F(ab')2 and Fab
in tumors. CancerRes 49: 5656-5663
Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP and Shawver
LK (1991) A monoclonal antibody against the c-erbB-2 protein enhances the
cytotoxicity ofcis-Diamminedichlorplatinum against human breast and ovarian
tumor cell lines. Cancer Res 51: 4575-4580
Hochuli E, Bannwarth W, Dobeli H, Gentz R and Stuber D (1988) Genetic approach
to facilitate purification ofrecombinant proteins with a novel metal chelate.
BiofTechnology 6: 1321-1325
Holliger P, Prospero T and Winter G (1993) 'Diabodies': small bivalent and
bispecific antibody fragments. Proc NatlAcad Sci USA 90: 6444-6448
Hu Shi-zhen SL, Raubitschek A, Sherman M, Williams LE, Wong JYC, Shively JE
and Wu AM (1996) Minibody: a novel engineered anti-carcinoembryonic
antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-
level targeting of xenografts. Cancer Res 56: 3055-3061
Huston JS, Levinson D, Mudgett-Hunter M, Tai M-S and Novotny J (1988) Protein
engineering ofantibody binding sites: recovery ofspecific activity in an
antidigoxin single-chain Fv analogue produced in E coli. Proc NatlAcad Sci
USA 85: 5879-5883
Huston JS, George AJT, Adams GP, Stafford WF, Jamar F, Tai M-S, McCartney JE,
Oppermann H, Heelan BT, Peters AM, Houston LL, Bookman MA, Wolf EJ
and Weiner LM (1996) Single-chain Fv radioimmunotargeting. Q JNucl Med
40: 320-333
Jain RK (1990) Physiological barriers to delivery ofmonoclonal antibodies and
other macromolecules in tumors. Cancer Res 50: (suppl.) 814s-819s
J0nsson U, Faegerstam L, Ivarsson B, Lundh K, L0fas S, Persson B, Roos H,
R0nnberg I, Sj0lander S, Stenberg E, Stahlberg R, Urbaniczky C, 0stlin H and
Malmqvist M (1991) Real-time biospecific interaction analysis using surface
plasmon resonance and a sensor chip technology. Bio Techniques 11: 620-627
Juweid MN, R Paik, Perez-Bacete C, M Sato, J van Osdol W and Weinstein JN
(1992) Micropharmacology of monoclonal antibodies in solid tumors: direct
experimental evidence for binding site barrier. Cancer Res 52: 5144-5153
Kaminski MS, Zasady KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford
SM, Burgess JM, Petry NA, Butchko GM, Glenn SD and Wahl RL (1993)
Radioimmunotherapy of B-cell lymphoma with 131I-anti-B I (anti-CD20)
antibody. New Engl JMed 329: 459-465
Karlson RA, Michaelsson A and Mattsson L (1991) Kinetic analysis of monoclonal
antibody-antigen interactions with a new biosensor based analytical system.
JImmunol Methodol 145: 229-240
King CR, Kraus MH and Aaronson SA (1985) Amplification of a novel v-erbB-
related gene in a human mammary carcinoma. Science 229: 974-976
Kraus MH, Popeseu NC, Amsbaugh SC and King CR (1987) Overexpression ofthe
EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell
lines by different molecular mechanisms. EMBO J 6: 605-610
Laub P and Gallo J (1996) NCOMP - a windows-based computer program for
noncompartmental analysis ofpharmacokinetic data. J Pharmaceut Sci 85:
393-395
Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD and Winter G
(1991) By-passing immunization. Human antibodies from V-gene libraries
displayed on phage. JMol Biol 222: 581-597
McCartney JE, Tai M-S, Hudziak RM, Adams GP, Weiner LM, Jin DJ,
Stafford III WF, Liu S, Bookman MA, Laminet AA, Fand I, Houston LL,
Oppermann H and Huston JS (1994). Engineering disulfide-linked single-chain
Fv dimers [(sFv')21 with improved solution and targeting properties: anti-
digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein
folding and bonded through C-terminal cysteinyl peptides. Protein Engineering
18: 301-314
Milenic DE, Yokota T, Filpula DR, Finkelman MAJ, Dodd SW, Wood JF, Whitlow
M, Snoy P and Schlom J (1991) Construction, binding properties, metabolism,
and targeting of a single-chain Fv derived from the pancarcinoma monoclonal
antibody CC49. Cancer Res 51: 6363-6371
Molthoff CFM, Pinedo HM, Schlupper HMM, Nijman HW and Boven E (1992)
Comparison of the pharmacokinetics, biodistribution and dosimetry of
monoclonal antibody OC125, OV-TL3 and 139H2 as IgG and F(ab')2
fragments in experimental ovarian cancer. Br J Cancer 65: 677-683
C) Cancer Research Campaign 1998 British Journal ofCancer(1998) 77(9), 1405-14121412 GPAdams etal
Pack PK, M Schroeckh V, Knupfer U, Wenderoth R, Riesenberg D and Pluckthun A
(1993) Improved bivalent miniantibodies, with identical avidity as whole
antibodies, produced by high cell density fermentation ofEscherichia coli.
BIO/Technology 11: 1271-1277
Pack PPA (1992) Miniantibodies: use ofamphipathic helices to produce functional,
flexably linked dimeric Fv fragments with high avidity in Escherichia coli.
Biochemistry 31: 1579-1584
Perisic 0, Webb PA, Hollinger P, Winter G and Williams RL (1994) Crystal
structure ofa diabody, a bivalent antibody fragment. Structure 2: 1217-1226
Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S,
Butchko G, Fisher D, Porter B, Matthews DC, Fischer LD and Bemstein ID
(1993) Radiolabeled-antibody therapy ofB-cell lymphoma with autologous
bone marrow support. New EnglJMed329: 1219-1224
Schier R, Marks JD, WolfE, Apell G, Wong C, McCartney J, Bookman M, Huston
J, Weiner L and Adams GP (1995) In vitro and in vivo characterization ofa
human anti-c-erbB2 single chain Fv isolated from a filamentous phage
antibody library. Immunotechnology 1: 73-81
Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS,
Weiner LM, Marks C and Marks JD (1996) Isolation ofpicomolar affinity anti-
c-erbB-2 single-chain Fv by molecular evolution ofthe complementarity
determining regions in the center ofthe antibody binding site. JMol Biol 263:
551-567
Siegel JA, Wessels BW, Watson EE, Stobin MG, Vriesendorp HM, Bradley EW,
Badger CC, Brill AB, Kwok CS, Stickney DR, Eckerman KF, Fisher DR,
Buchsbaum DJ and Order SE (1990) Bone marrow dosimetry and toxicity for
radioimmunotherapy. AntibodyImmunoconj Radiopharmaceut 3: 213-233
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL (1987)
Human breast cancer: correlation ofrelapse and survival with amplification of
the HER-2lneu oncogene. Science 235: 177-182
Stein R, Chen S, Sharkey RM and Goldenberg DM (1991) Radioimmunotherapy of
human non-small cell carcinoma ofthe lung xenografts with '3'I-labeled
monoclonal antibody RS7-3G 11. AntibodyImmunoconj Immunopharmaceut 4:
703-712
Stein R, Blumenthal R, Sharkey RM and Goldenberg DM (1994) Comparative
biodistribution and radioimmunotherapy ofmonoclonal antibody RS7 and its
F(ab')2 in nude mice bearing human tumor xenografts. Cancer 73: 816-823
van de Vijver M, van de Bersselaar R, Devilee P, Comelisse C, Peterse J and Nusse
R (1987) Amplification ofthe neu (c-erbB-2) oncogene in human mammary
tumors is relatively frequent and is often accompanied by amplification ofthe
linked c-erbA oncogene. Mol Cell Biol 7: 2019-2023
Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W and Ullrich, A (1995)
Heregulin-dependent regulation ofHER2./neu oncogenic signaling by
heterodimerization with HER3. EMBO J 14: 4267-4275
Ward ES, Gussow D, Griffiths AD, Jones PT and Winter G (1989) Binding activities
ofa repertoire of single immunoglobulin variable domains secreted from
Escherichia coli. Nature 341: 544-546
Weiner LM, Holmes M, Richeson A, Godwin A, Adams GP, Hsieh-Ma ST, Ring DB
and Alpaugh RK (1993) Binding and cytotoxicity characteristics ofthe
bispecific murine monoclonal antibody 2B1. Jlmmunol 151: 2877-2887
Weiner LM, Houston LL, Huston JS, McCartney JE, Tai M-S, Apell G, Stafford WF,
Bookman MA, Gallo JM and Adams GP (1995) Improving the tumor-selective
delivery ofsingle-chain Fv molecules. Tumor Targeting 1: 51-60
WolfEA, Schreiber GJ, Cosand WL and RaffHV (1993) Monoclonal antibody
homodimers: enhanced antitumor activity in nude mice. Cancer Res 53:
2560-2565
Yokota T, Yamamoto T, Miyajima N, Toyoshima K, Nomura N, Sakamoto H,
Yoshida T, Terada M and Sugimura T (1988) Genetic alterations ofthe c-erbB2
oncogene occur frequently in tubular adenocarcinoma ofthe stomach and are
often accompanied by amplification ofthe v-erbA homologue. Oncogene 2:
283-287
Yorke ED, Beaumier PL, Wessels BW, Fritzberg AR and Morgan C (1991) Optimal
antibody-radionuclide combinations for clinical radioimmunotherapy: a
predictive model based upon mouse pharmacokinetics. Nucl MedBiol IntJ
RadiatAppl Instrum Part B 18: 827-835
British Journal ofCancer (1998) 77(9), 1405-1412 © CancerResearch Campaign 1996